Efficacy of aspirin for secondary prevention in patients with peripheral artery disease

References

• Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation110, 738–743 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA286, 1317–1324.
   Google Scholar
• Weitz JI, Byrne J, Clagett GP et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation94, 3026–3049 (1996).
   PubMed Web of Science ®Google Scholar
• Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. Surgery78, 795–799 (1975).
   PubMed Web of Science ®Google Scholar
• Dormandy J, Mahir M, Ascady G et al. Fate of the patient with chronic leg ischaemia: a review article. J. Cardiovasc. Surg. (Torino)30, 50–57 (1989).
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Murray GD, Butcher I et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA300, 197–208 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aorta): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation113, e463–e654 (2006).
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ308, 81–106 (1994).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Catalano M, Born G, Peto R; Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J. Intern. Med.261, 276–284 (2007).
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ337, a1840 (2008).
   PubMed Web of Science ®Google Scholar
• Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA301, 1909–1919 (2009).
   PubMed Web of Science ®Google Scholar
• McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J. Vasc. Surg.13, 150–161 (1991).
   Google Scholar
• Colwell JA, Bingham SF, Abraira C et al. VA Cooperative study of antiplatelet agents in diabetic patients after amputation for gangrene: unobserved, sudden, and unexpected deaths. J. Diabet. Complications3, 191–197 (1989).
   Google Scholar
• Ogawa H, Nakayama M, Morimoto T et al.; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with Type 2 diabetes: a randomized controlled trial. JAMA300, 2134–2141 (2008).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med.354, 1706–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur. Heart J.30, 192–201 (2009).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol.49, 1982–1988 (2007).
   PubMed Web of Science ®Google Scholar
• Price JF, Stewart MC, Deary IJ et al.; AAA Trialists. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ337, A1198 (2008).
   PubMed Web of Science ®Google Scholar